Grail股价下跌,尽管亏损收窄但收入未达预期

英为财情
Aug 13, 2025

Investing.com -- 专注于早期癌症检测的医疗保健公司GRAIL, Inc. (NASDAQ:GRAL)在发布2025年第二季度财报后股价下跌3.3%,尽管公司亏损幅度小于预期,但收入未能达到分析师预期。 这家癌症检测公司报告第二季度总收入为3550万美元,低于分析师预期的3690万美元,但同比增长11%。占公司业务主要部分的Galleri检测收入同比增长22%,达到3440万美元。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10